Sugi Predict

Sugi Predict / Compounds / SCHEMBL2947202

SCHEMBL2947202

SCHEMBL2947202

Cc1c(C(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c(=O)n(-c2ccccc2)n1CC(C)(C)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 16/20 0.57
▸ FLT3 P36888 16/20 0.57
▸ KDR P35968 18/20 0.54
▸ CSF1R P07333 4/20 0.54
▸ FLT1 P17948 4/20 0.54
▸ FLT4 P35916 4/20 0.54
▸ LCK P06239 3/20 0.54
▸ PLK4 O00444 3/20 0.54
▸ AURKA O14965 3/20 0.54
▸ ROCK2 O75116 3/20 0.54
▸ INSR P06213 3/20 0.54
▸ MET P08581 3/20 0.54
▸ FGFR1 P11362 3/20 0.54
▸ PRKACA P17612 3/20 0.54
▸ RPS6KB1 P23443 3/20 0.54
▸ CSNK1D P48730 3/20 0.54
▸ STK3 Q13188 3/20 0.54
▸ ROCK1 Q13464 3/20 0.54
▸ NTRK2 Q16620 3/20 0.54
▸ MARK2 Q7KZI7 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953100 0.90 KDR (0.53) KITFLT3KDRCSF1RFLT1
SCHEMBL24807410 0.83 KDR (0.54) KITFLT3KDRCSF1RLCK
SCHEMBL30084616 0.83 KDR (0.54) KITFLT3KDRCSF1RLCK
SCHEMBL15844536 0.76 MET (0.56) KITFLT3KDRCSF1RFLT1
SCHEMBL2954266 0.75 KDR (0.59) KITFLT3KDRCSF1RFLT1
SCHEMBL2953840 0.74 MET (0.59) KITFLT3KDRCSF1RLCK
SCHEMBL31060160 0.74 KIT (1.00) KITFLT3KDRCSF1RFLT1
SCHEMBL2945012 0.73 MET (0.48) KITFLT3KDRCSF1RLCK
SCHEMBL2948094 0.73 MET (0.48) KITFLT3KDRCSF1RLCK
SCHEMBL2950401 0.72 MET (0.53) KITFLT3KDRCSF1RLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759344-B2 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2010-07-20 — — US disclosed
US-7759344-B2 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2010-07-20 — — US disclosed
US-7759344-B2 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2010-07-20 — — US disclosed
EP-2118069-A2 BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2009-11-18 — — EP disclosed
US-20080234268-A1 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2008-09-25 — — US disclosed
US-20080234268-A1 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2008-09-25 — — US disclosed
US-20080234268-A1 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2008-09-25 — — US disclosed
WO-2008086014-A2 BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2008-07-17 — — WO disclosed
WO-2008086014-A2 BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2008-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234268-A1 Bis-aryl amide derivatives and methods of use MET, REL, NAT1 KIT 663/4885FLT3 55/4885KDR 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.